Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022
Dispatch

SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan

Wendelin Moser, Mohammed Ahmed Hassan Fahal1, Elamin Abualas1, Shahinaz Bedri, Mahgoub Taj Elsir, Mona Fateh El Rahman Omer Mohamed, Abdelhalim Babiker Mahmoud, Amna Ismail Ibrahim Ahmad, Mohammed A. Adam, Sami Altalib, Ola Adil DafaAllah, Salahaldin Abdallah Hmed, Andrew S. Azman, Iza Ciglenecki, Etienne Gignoux, Alan González, Christine Mwongera, and Manuel Albela MirandaComments to Author 
Author affiliations: Médecins Sans Frontières, Geneva, Switzerland (W. Moser, A.S. Azman, I. Ciglenecki, A. González, C. Mwongera, M. Albela Miranda); Médecins Sans Frontières, Khartoum (M.T. Elsir, A.B. Mahmoud, A.I.I. Ahmad, M.A. Adam, S. Altalib, O.A. DafaAllah, S.A. Hmed); Khartoum State Ministry of Health, Khartoum, Sudan (M.AH. Fahal, E. Abualas, S. Bedri, M.T. Elsir, M.F.E.R.O. Mohamed, O.A. DafaAllah); National Public Health Laboratory, Khartoum (E. Abualas, S. Bedri, O.A. DafaAllah); University of Khartoum, Khartoum (A.B. Mahmoud, M.A. Adam, S. Altalib); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (A.S. Azman); University of Geneva, Geneva (A.S. Azman); Epicentre, Paris, France (E. Gignoux)

Main Article

Table 2

Reported death rates for the prepandemic and pandemic periods from cross-sectional SARS-CoV-2 survey, Omdurman, Sudan*

Age group Overall
 Prepandemic period
 Pandemic period
 Rate ratio
No. deaths Rate (95% CI) No. deaths Rate (95% CI) No. deaths Rate (95% CI) Rate ratio (95% CI) p value
<5 y 30 0.19 (0.10–0.28) 18 0.22 (0.11–0.32) 12 0.17 (0.04–0.30) 0.77 (0.34–1.70) 0.613
5–19 y 13 0.02 (0.01–0.03) 2 0.00 (0.00–0.01) 11 0.03 (0.01–0.05) Referent NA
20–34 y 30 0.05 (0.03–0.07) 10 0.04 (0.01–0.06) 20 0.07 (0.04–0.11) 1.75 (0.78–4.19) 0.199
35–49 y 40 0.12 (0.09–0.16) 16 0.09 (0.05–0.14) 24 0.15 (0.09–0.21) 1.67 (0.85–3.36) 0.149
>50 y
 206
 0.78 (0.65–0.91)
80
 0.57 (0.45–0.69)
126
 0.99 (0.79–1.20)
1.74 (1.30–2.33)
 <0.001
Total 319 0.16 (0.13–0.18) 126 0.12 (0.10–0.14) 193 0.20 (0.16–0.23) 1.67 (1.32–2.10) <0.001

*No. deaths per category are reported rates. NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

1These authors contributed equally to this article.

Page created: March 28, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external